Novartis has entered into a definitive agreement to acquire Excellergy, a privately held biotechnology company specializing in the development of…
Read More
Darzalex Secures Landmark European Approval for Self-Administration in Multiple Myeloma, Ushering in a New Era of Home-Based Cancer Care
Johnson & Johnson’s (J&J) groundbreaking cancer immunotherapy, Darzalex (daratumumab), has achieved a pivotal milestone in its European market penetration with…
Read More
Europe’s Biopharmaceutical Competitiveness and Commercial Strategies Under Scrutiny at BIO Europe Spring
Lisbon, Portugal – As the vibrant city of Lisbon recently concluded its tenure as host for the annual BIO Europe…
Read More
Recordati Weighs CVC’s €10.9 Billion Acquisition Offer, Potentially Delisting from Italian Stock Exchange
Italian pharmaceutical giant Recordati is currently in deliberations regarding a significant acquisition offer from global private equity firm CVC Capital…
Read More
Rocket Pharmaceuticals Secures Landmark FDA Approval for Kresladi, Ushering in a New Era for Ultra-Rare Immune Disease Treatment
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Rocket Pharmaceuticals’ Kresladi (marnetegragene autotemcel), a groundbreaking gene…
Read More
Corcept’s first-in-class ovarian cancer drug gains FDA approval – Pharmaceutical Technology
Corcept Therapeutics has achieved a significant milestone with the U.S. Food and Drug Administration (FDA) granting approval for its selective…
Read More
Daiichi Sankyo and Tempus AI collaborate on ADC clinical development
In a significant move poised to accelerate the innovation pipeline for antibody-drug conjugate (ADC) therapies, Japanese pharmaceutical giant Daiichi Sankyo…
Read More
Cognito Therapeutics and Ochsner Health Forge Landmark Partnership to Advance Brain Health Innovation in the Gulf South
A groundbreaking collaboration has been established between US-based neurotechnology firm Cognito Therapeutics and Ochsner Health, a leading integrated healthcare system…
Read More
The US Food and Drug Administration Convenes Public Hearing Amidst Scrutiny of Commissioner’s National Priority Voucher Program
The US Food and Drug Administration (FDA) is set to convene a significant public hearing on June 12, 2026, a…
Read More
The Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals Plummet
On May 12, 2025, a significant executive order signed by then-US President Donald Trump mandated the US Department of Health…
Read MoreYOU MAY HAVE MISSED
